Moxifloxacin Concentrations in the Knee Joint, Tibial Bone, and Soft Tissue When Combined with Rifampicin: A Randomized Porcine Microdialysis Study

• Published in: Journal of bone and joint surgery. American volume Vol. 104; no. 1; pp. 49 - 54
• Main Authors: Slater, Josefine, Stilling, Maiken, Hanberg, Pelle, Fichtner Bendtsen, Mathias Alrø, Jørgensen, Andrea René, Søballe, Kjeld, Jørgensen, Nis Pedersen, Bue, Mats
• Format: Journal Article
• Language: English
• Published: United States Journal of Bone and Joint Surgery, Inc 05-01-2022
• Subjects: Administration, Oral; Animals; Area Under Curve; Drug Therapy, Combination; Female; Knee Joint - metabolism; Microdialysis; Moxifloxacin - administration & dosage; Moxifloxacin - pharmacokinetics; Prosthesis-Related Infections - prevention & control; Rifampin - administration & dosage; Rifampin - pharmacokinetics; Subcutaneous Tissue - metabolism; Swine; Tibia - metabolism
• ISSN: 0021-9355; 1535-1386
• DOI: 10.2106/JBJS.21.00549

Peri and postoperative antibiotics are key adjuvant treatment tools in the management of periprosthetic joint infection (PJI). The aim of this study was to evaluate the effect of rifampicin on the area under the moxifloxacin concentration-time curve from 0 to 24 hours (AUC0-24) in the synovial fluid of the knee joint, tibial bone, and adjacent subcutaneous tissue under steady-state conditions using microdialysis in a porcine model.
Twenty female pigs were randomized to receive oral treatment with moxifloxacin monotherapy (Group A, n = 10) of 400 mg once daily for 3 days or a combination therapy (Group B, n = 10) of 400 mg of moxifloxacin once daily for 3 days and 450 mg of rifampicin twice daily for 7 days. Microdialysis was used for sampling the synovial fluid of the knee joint, tibial cancellous and cortical bone, and adjacent subcutaneous tissues. Plasma samples were taken as a reference. Measurements were obtained for 24 hours.
Coadministration of moxifloxacin and rifampicin resulted in reductions of the moxifloxacin AUC0-24 in all targeted tissue compartments by 67% to 85% (p < 0.05). The corresponding change in plasma was 20% (p = 0.49). For both groups, the tissue penetration (the ratio of tissue free fraction AUC0-24 to plasma free fraction AUC0-24 [fAUCtissue/fAUCplasma]) was incomplete in all investigated compartments. The highest moxifloxacin tissue penetration was in the knee joint synovial fluid: 0.59 (Group A) and 0.24 (Group B). The lowest tissue penetration was in the cortical bone: 0.17 (Group A) and 0.03 (Group B).
We found a significant reduction of the moxifloxacin concentration, expressed as the AUC0-24, in tissues relevant to acute PJI treatment when coadministered with rifampicin.
The concentrations within the targeted tissue compartments were reduced significantly more than the concentrations in plasma, which may be particularly important as plasma concentrations are used in clinical practice to assess moxifloxacin treatment sufficiency.